These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8889966)

  • 1. Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis.
    Moreau R; Cailmail S; Hamon G; Lebrec D
    J Gastroenterol Hepatol; 1996 Sep; 11(9):857-63. PubMed ID: 8889966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis.
    Gadano A; Moreau R; Pessione F; Trombino C; Giuily N; Sinnassamy P; Valla D; Lebrec D
    J Hepatol; 2000 Jan; 32(1):38-42. PubMed ID: 10673065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.
    Bellissant E; Denolle T; Sinnassamy P; Bichet DG; Giudicelli JF; Lecoz F; Gandon JM; Allain H
    J Pharmacol Exp Ther; 1996 Jul; 278(1):232-42. PubMed ID: 8764356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Jiménez W; Angeli P; Leivas A; Clària J; Graziotto A; Arroyo V; Rivera F; Rodés J
    Gastroenterology; 1995 Jul; 109(1):217-23. PubMed ID: 7797019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of niravoline (RU 51599), a selective kappa-opioid receptor agonist on intracranial pressure in gradually expanding extradural mass lesion.
    Bemana I; Nagao S
    J Neurotrauma; 1998 Feb; 15(2):117-24. PubMed ID: 9512087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niravoline, a selective kappa-opioid receptor agonist effectively reduces elevated intracranial pressure.
    Nagao S; Bemana I; Kuratani H; Takahashi E; Nakamura T
    Exp Brain Res; 2000 Feb; 130(3):338-44. PubMed ID: 10706433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
    Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema.
    Takahashi H; Hamada H; Teramoto A
    Acta Neurochir (Wien); 1999; 141(7):771-8. PubMed ID: 10481790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kappa opioid agonist niravoline decreases brain edema in the mouse middle cerebral artery occlusion model of stroke.
    Guéniau C; Oberlander C
    J Pharmacol Exp Ther; 1997 Jul; 282(1):1-6. PubMed ID: 9223533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of niravoline, an arginine vasopressin inhibitor, on tumour-origin brain oedema.
    Takahashi H; Hamada H; Teramoto A
    Acta Neurochir Suppl; 2000; 76():323-7. PubMed ID: 11450035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis.
    Komeichi H; Moreau R; Cailmail S; Gaudin C; Lebrec D
    J Hepatol; 1995 Mar; 22(3):319-25. PubMed ID: 7608483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central kappa opioid receptor-evoked changes in renal function in conscious rats: participation of renal nerves.
    Kapusta DR; Obih JC
    J Pharmacol Exp Ther; 1993 Oct; 267(1):197-204. PubMed ID: 8229746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cardiovascular and renal responses produced by microinjection of the {kappa}-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus.
    Gottlieb HB; Varner KJ; Kenigs VA; Cabral AM; Kapusta DR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):678-85. PubMed ID: 15381735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aquaretic agents].
    Jiménez W
    Nefrologia; 2002; 22 Suppl 5():52-5. PubMed ID: 12107918
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of renal nerves in excretory responses to administration of kappa agonists in conscious spontaneously hypertensive rats.
    Kapusta DR; Jones SY; DiBona GF
    J Pharmacol Exp Ther; 1989 Oct; 251(1):230-7. PubMed ID: 2552076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal excretory responses produced by central administration of opioid agonists in ketamine and xylazine-anesthetized rats.
    Cabral AM; Varner KJ; Kapusta DR
    J Pharmacol Exp Ther; 1997 Aug; 282(2):609-16. PubMed ID: 9262322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kappa opioid-induced diuresis in female vs. male rats.
    Craft RM; Ulibarri CM; Raub DJ
    Pharmacol Biochem Behav; 2000 Jan; 65(1):53-9. PubMed ID: 10638636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of alpha-2 adrenoceptors to kappa opioid agonist-induced water diuresis in the rat.
    Wang YX; Clarke GD; Sbacchi M; Petrone G; Brooks DP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):244-9. PubMed ID: 8035321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central kappa opioids blunt the renal excretory responses to volume expansion by a renal nerve-dependent mechanism.
    Kapusta DR; Obih JC
    J Pharmacol Exp Ther; 1995 Apr; 273(1):199-205. PubMed ID: 7714767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.